Related Experiment Video
Updated: Jul 19, 2026
07:56
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
Published on: January 26, 2018
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
1Indiana University School of Medicine, Notre Dame Cancer Institute, South Bend, IN 46617, USA. navari.1@nd.edu
Future Oncology (London, England)
|October 10, 2006
Summary
Palonosetron effectively prevents chemotherapy-induced nausea and vomiting (CINV), including delayed symptoms, offering improved patient quality of life. This new 5-hydroxytryptamine (5-HT)3 receptor antagonist shows high efficacy and safety in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Chemotherapy-induced nausea and vomiting (CINV) significantly impairs patient quality of life.
- First-generation 5-hydroxytryptamine (5-HT)3 receptor antagonists with dexamethasone improve acute CINV control, but delayed CINV remains a challenge.
- Patient-specific factors like gender, age, alcohol use, and motion sickness history increase CINV risk.
Purpose of the Study:
- To evaluate the efficacy and safety of palonosetron for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV).
- To compare palonosetron with existing 5-HT3 receptor antagonists in managing CINV.
- To explore palonosetron's utility in various chemotherapy regimens and clinical settings.
Main Methods:
- Clinical trials comparing single-dose palonosetron with dolasetron or ondansetron for moderately emetogenic chemotherapy.
- Studies assessing palonosetron in combination with dexamethasone for highly emetogenic chemotherapy.
- Evaluation of palonosetron's effectiveness across multiple chemotherapy cycles and in different patient populations.
Main Results:
- Palonosetron demonstrated high efficacy in controlling acute CINV compared to ondansetron or dolasetron in moderately emetogenic chemotherapy.
- Palonosetron combined with dexamethasone effectively controlled CINV in patients receiving highly emetogenic chemotherapy.
- Palonosetron exhibited consistent efficacy across subsequent chemotherapy courses, with no significant safety concerns compared to other 5-HT3 receptor antagonists.
Conclusions:
- Palonosetron is a valuable agent for preventing both acute and delayed CINV, particularly in patients undergoing moderately or highly emetogenic chemotherapy.
- Its longer half-life and higher binding affinity contribute to its superior efficacy over first-generation agents.
- Further research into palonosetron-based combinations and its use in diverse settings like bone marrow transplantation and radiation therapy is warranted.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...